Point72 Asset Management
VYNE icon

Point72 Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Point72 Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,949
Closed -$352K – 1153
2020
Q3 		$352K Buy
+2,949
New +$344K ﹤0.01% 844
2020
Q2 		– Sell
-13,889
Closed -$2.68M – 1045
2020
Q1 		$2.68M Buy
+13,889
New +$4.36M 0.02% 469

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Point72 Asset Management's VYNE Position: Q4 2020 in Review

Point72 Asset Management sold out of VYNE Therapeutics (VYNE) in Q4 2020, closing a stake of 2,949 shares — an estimated $352K sold.

Point72 Asset Management first reported a position in VYNE in Q1 2020 and held it in 2 quarters. The position peaked at $2.68M in Q1 2020. 104 funds tracked by Wall St. Rank hold VYNE as of Q4 2020.

  • Point72 Asset Management reported no remaining VYNE Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Point72 Asset Management sold 2,949 VYNE Therapeutics shares in Q4 2020, an estimated $352K.
  • Point72 Asset Management first reported a position in VYNE Therapeutics in Q1 2020 and held it in 2 quarters.
  • Point72 Asset Management's VYNE Therapeutics position peaked at $2.68M in Q1 2020.
  • 104 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2020.

Based on Point72 Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.